The Latest Breaking News from Vaccine

Here's a roundup of top developments in the biotech space over the last 24 hours:

The booster contains the original vaccine with an updated version that specifically targets the Omicron variant.

Novavax Inc (NASDAQ: NVAX) shares are trading higher Wednesday after a committee of independent U.S. Food and Drug Administration (FDA) vaccine advisors voted to recommend Novavax's COVID-19 vaccine for Emergency Use Authorization (EUA).

CNBC

After last week's scare stirred by the release of the Food And Drug Administration's briefing documents, Novavax (NASDAQ: NVAX) can now heave a sigh of relief.

Experts hope the newer jabs could protect against a wider range of variants.

The "bivalent" vaccine — meaning it targets two different antigens — is Moderna's leading candidate for an effective booster this fall. If the data pan out, it could lead to a yearly booster.

Moderna says its experimental COVID-19 vaccine that combines its original shot with protection against the omicron variant appears to work

Moderna Inc said on Wednesday its COVID-19 vaccine booster that targets both the original coronavirus strain and Omicron produced a better immune response against the variant than its original vaccine. The booster raised virus-neutralizing antibodies by eight-fold in a study.

Moderna Inc said on Wednesday a new version of its coronavirus vaccine produced a better immune response against Omicron than the original shot, as the drugmaker pursues a booster against a surge in infections in the fall season.

In a telephone interview with Reuters, WTO's Director-General Ngozi Okonjo-Iweala, an agreement on waiving intellectual property rights for COVID-19 vaccines is within reach. A key World Trade Organization (WTO) meeting is scheduled next week to discuss the COVID-19 vaccine patent waiver debate. "If we get one or two deliverables, that…